

Vaccine Supply

Advisory Committee on Immunization Practices

October 24, 2007

Gregory S. Wallace , M.D., M.S., M.P.H.

Chief, Vaccine Supply and Assurance Branch

Immunization Services Division

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention



SAFER • HEALTHIER • PEOPLE™

Hepatitis A Vaccine (July 2007)

- CDC informed of vaccine supply issue by Merck
- Backorders of Pediatric and Adult VAQTA[®]
- Supply in after September not known
- Adequate supply available from GSK
- No Change in ACIP recommendation



Hepatitis A Vaccine (Current Status)

- VAQTA® orders suspended for Adult & Pediatric Vial Formulation
- Estimated return to market late 1st Qtr '08
- Adequate supply available from GSK
- No Change in ACIP recommendation



Update on Varicella-Based Vaccine Supply

- **Varicella Zoster Virus (VZV) Bulk is used to Manufacture**
 - **Varicella Vaccine**
 - **MMR-V Vaccine**
 - **Zoster Vaccine**



VZV Bulk Process

- Lower than Expected Yields
- Temporary Suspension of Production
- Adequate Bulk available to produce varicella and zoster vaccine
- No Changes in Current Vaccine Policy Recommendations



MMWR Notice to Readers

- **Feb 23, 2007**
 - Prioritize production of Varicella vaccine and Zoster Vaccine
 - Expect depletion of MMR-V by end of 2007
- **May 11, 2007**
 - Expect depletion of MMR-V by end of July, 2007



Current MMR-V Supply

- ProQuad[®] orders suspended in June
- Remediation process in progress
- Current VZV Bulk adequate to produce varicella and zoster vaccine
- Varivax[®] shipping delays have ranged from 3-4 weeks to 6-7 weeks



Summary

- No Change in recommendation for vaccination to protect against varicella disease
- Varicella vaccine (Varivax) supply adequate to meet needs
- Remediation process for resuming MMR-V in progress




Influenza Update

- History of Influenza Vaccine Production
- History of Influenza Vaccine Distribution
- Update on Current Influenza Vaccine Season



Projecting Demand in a Changing World (Influenza)




* 2007 Projected Production



SAFER • HEALTHIER • PEOPLE™

Cumulative Monthly Influenza Vaccine Distribution


(*Through 10/19/2007)



SAFER • HEALTHIER • PEOPLE™

Projecting Demand in a Changing World

(Pediatric Vaccines)



SAFER • HEALTHIER • PEOPLE™

Public Sector Demand

Vaccine	2005	2006	2007 (through 8/31/2007)
MCV4	1.4 of 3.1 (46%)	1.7 of 4.2 (40%)	2.0 of 5.1 (39%)
Tdap	1.1 of 4.7 (24%)	3.7 of 9.2 (41%)	2.4 of 9.9 (24%)
HPV	---	1.1 of 2.2 (50%)	2.9 of 8.1 (36%)

Tdap available 4 months in public sector in 2005, 6 months in private sector

HPV available 2 months in public sector in 2006, 6 months in private sector



Adolescent Implementation Status

- Purchases of MCV4 steadily increasing, will be >1 cohort this year
- Grantees purchased ~2 cohorts of Tdap in 2006, level in 2007
 - Increase in Private Sector in 2007
- Private Sector purchases for HPV now outpace public sector



Caveats

- Much of 2007 demand occurred during 3rd quarter (back to school)
- Transition to 3rd party distributor requires inventory
- Not clear if demand will meet inventory during implementation
- Difficult to evaluate trends and proportion going to adults vs adolescents

